About Tempus
Tempus is a company based in Chicago (United States) founded in 2015 by Eric Lefkofsky. It operates as a AI-as-a-Service, Data-as-a-Service, and Professional Services. Tempus has raised $760 million across 9 funding rounds from investors including Google, T. Rowe Price and Franklin Templeton. The company has 2,400 employees as of December 31, 2024. Tempus has completed 5 acquisitions, including Ambry Genetics, Deep 6 AI and Highline SCIENCES. Tempus offers products and services including Tempus One, Tempus Lens, Tempus xM, and Tempus Pixel. Tempus operates in a competitive market with competitors including Personalis, CancerIQ, Perthera, LinkDoc and Trapelo, among others.
- Headquarter Chicago, United States
- Employees 2400 as on 31 Dec, 2024
- Founders Eric Lefkofsky
- Stage Unicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Tempus Ai, Inc.
-
Annual Revenue
$693.4 M (USD)30.38as on Dec 31, 2024
-
Net Profit
-$705.81 M (USD)-229.64as on Dec 31, 2024
-
EBITDA
-$651.14 M (USD)-299.1as on Dec 31, 2024
-
Total Equity Funding
$760 M (USD)
in 9 rounds
-
Latest Funding Round
$460 M (USD), Post-IPO
Jul 30, 2026
-
Investors
Google
& 7 more
-
Employee Count
2400
as on Dec 31, 2024
-
Investments & Acquisitions
Ambry Genetics
& 4 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Tempus
Tempus is a publicly listed company on the NASDAQ with ticker symbol TEM in USA, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Tempus
Tempus offers a comprehensive portfolio of products and services, including Tempus One, Tempus Lens, Tempus xM, and Tempus Pixel.
AI assistant for healthcare providers and researchers.
Platform for accessing multimodal real-world data analysis.
Assay for monitoring immunotherapy response in cancers.
Imaging solutions for therapy response evaluation purposes.
People of Tempus
Unlock access to complete
Unlock access to complete
Leadership Team
136 people
Software Development Team
114 people
Operations Team
100 people
Sales and Marketing
47 people
Senior Team
34 people
Data Analysis and Operations Team
25 people
Product Management Team
14 people
Human Resources and Administration
11 people
Unlock access to complete
Funding Insights of Tempus
Tempus has successfully raised a total of $760M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $460 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tempus
Tempus has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Google, T. Rowe Price and Franklin Templeton.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Revolution is recognized as a D.C.-based investment firm.
|
Locked | Locked | Locked |
Investor details for Tempus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tempus
Tempus has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Ambry Genetics, Deep 6 AI and Highline SCIENCES.
Investment portfolio details for Tempus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
CRO focused on clinical development services for oncology drugs
|
Locked | Locked | 2018 | Locked | |
|
AI-enabled tools for computational pathology and cancer diagnostics are provided.
|
Locked | Locked | 2018 | Locked | |
|
AI enabled solutions for clinical trials
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Tempus
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Tempus
Detailed financials for Tempus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tempus Comparisons
Peer comparison for Tempus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tempus
Tempus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Personalis, CancerIQ, Perthera, LinkDoc and Trapelo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
CancerIQ is focused on precision cancer prevention and care.
|
|
| Locked | Locked | Locked |
Molecular cancer profiling is conducted via genomics and proteomics.
|
|
| Locked | Locked | Locked |
Oncology-focused database is provided for cancer analytics.
|
|
| Locked | Locked | Locked |
Precision medicine platform is provided for oncologists' decision support.
|
Detailed competitors of Tempus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tempus
Complete news archive for Tempus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tempus
Tempus was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Tempus is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Eric Lefkofsky is the current CEO of Tempus. They have also founded this company.
Tempus is a funded company, having raised a total of $760M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Tempus is 2,400.
Annual revenue of Tempus is $693.4M as on Dec 31, 2024.
Tempus is engaged in developing AI-enabled precision medicine solutions for healthcare providers, life sciences, and patients. The company operates in sectors such as oncology, neurology, psychiatry, cardiology, and radiology. Solutions offered include genomic profiling, clinical trial matching, real-world data analysis, and diagnostic imaging. Through extensive research and partnerships, Tempus is committed to accelerating personalized patient care and transforming drug development for pharmaceutical companies. Its technology integrates with electronic health records to enhance workflow and close care gaps.
Tempus's top competitors include Personalis, CancerIQ and Perthera.
Tempus offers Tempus One, Tempus Lens, Tempus xM, and Tempus Pixel.
Yes, Tempus is publicly traded on NASDAQ under the ticker symbol TEM.
Tempus has made 5 acquisitions, including Ambry Genetics, Deep 6 AI, and Highline SCIENCES.
Tempus has 8 investors. Key investors include Google, T. Rowe Price, Franklin Templeton, Baillie Gifford, and Novo Holdings.
The ticker symbol of Tempus is TEM on NASDAQ.
The valuation of Tempus is $8.1B as of Dec 2020.